Evidence map›Paper›PMID 31353798›Full record

ArticleJournal of the International AIDS Society2019

Near full genome characterization of HIV-1 unique recombinant forms in Cameroon reveals dominant CRF02_AG and F2 recombination patterns.

Andrew N Banin, Michael Tuen, Jude S Bimela, Marcel Tongo, Paul Zappile, Alireza Khodadadi-Jamayran, Aubin J Nanfack, Iheanyi O Okonko, Josephine Meli, Xiaohong Wang and 6 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Development and genomic characterization of a diverse HIV-1 variant reference panel for nucleic acid-based testing.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrew N BaninDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Michael TuenDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Jude S BimelaDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Marcel TongoCenter of Research for Emerging and Re-Emerging Diseases (CREMER), Institute of Medical Research and Study of Medicinal Plants, Yaoundé, Cameroon.
Paul ZappileDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Alireza Khodadadi-JamayranApplied Bioinformatics Laboratories (ABL) and Genome Technology Center (GTC), Division of Advanced Research Technologies (DART), New York University Langone Medical Center, New York, NY, USA.
Aubin J NanfackDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Iheanyi O OkonkoVirus Research Unit, Department of Microbiology, University of Port Harcourt, Port Harcourt, Nigeria.
Josephine MeliMedical Diagnostic Center, Yaoundé, Cameroon.
Xiaohong WangManhattan Veterans Affairs Harbor Healthcare Systems, New York, NY, USA.
Dora MbanyaFaculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Jeanne NgogangFaculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Miroslaw K GornyDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Adriana HeguyDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Charles FokunangFaculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
Ralf DuerrDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0001-9569-9237

Funding

Welcome Trust 107Welcome Trust 752/Z/15/Z
6 · The paper itself

Abstract

introductionIn Cameroon, a manifold diversity of HIV strains exists with CRF02_AG and unique recombinant forms (URFs) being the predominant strains. In recent years, a steady increase in URFs and clade F2 viruses has been monitored through partial genome sequencing. There is an information gap in the characterization of emerging URFs along the full genome, which is needed to address the challenges URFs pose towards diagnosis, treatment and HIV-1 vaccine design.

methodEighteen Cameroonian URFs from samples collected between the years 2000 and 2015 were studied using a newly developed near full genome sequencing (NFGS) protocol based on variable nested RT-PCRs with a versatile primer set. Near full genomes were characterized for recombination patterns and sequence signatures with possible impact on antiretroviral treatment or Env-directed immune responses. Third-generation sequencing (3GS) of near full or half genomes (HGs) gave insight into intra-patient URF diversity.

resultsThe characterized URFs were composed of a broad variety of subtypes and recombinants including A, F, G, CRF01_AE, CRF02_AG and CRF22_01A1. Phylogenetic analysis unveiled dominant CRF02_AG and F2 recombination patterns. 3GS indicated a high intra-patient URF diversity with up to four distinct viral sub-populations present in plasma at the same time. URF pol genomic analysis revealed a number of accessory drug resistance mutations (DRMs) in the ART-naïve participants. Genotypic env analysis suggests CCR5 usage in 14/18 samples and identified deviations at residues, critical for gp120/gp41 interphase and CD4 binding site broadly neutralizing antibodies in more than half of the studied URFs. V1V2 sites of immune pressure in the human RV144 vaccine study varied in more than a third of URFs.

conclusionsThis study identified novel mosaic patterns in URFs in Cameroon. In line with the regional predominance of CRF_02AG and the increased prevalence of clade F2, prominent CRF_02AG and F2 background patterns were observed underlying the URFs. In the context of the novel mosaic genomes, the impact of the identified accessory DRMs and Env epitope variations on treatment and immune control remains elusive. The evolving diversity of HIV-1 URFs in Cameroon requires continuous monitoring to respond to the increasing challenges for diagnosis, antiretroviral treatment and prevention.

Indexed as

HIV SeropositivityAnti-HIV AgentsCameroonFemaleGenome, ViralHIV-1HIV InfectionsHumansLongitudinal StudiesMutationPhylogenyPolymerase Chain ReactionReassortant VirusesAnti-HIV AgentsEnv epitopes and drug resistance mutationsintra-patient viral diversitynear full genome sequencingthird-generation sequencingunique recombinant forms

Identifiers

PMID31353798
PMCPMC6661401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.